Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …

The presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the
plasma or serum of cancer patients was first demonstrated 30 years ago. Since then, overall …

BACKGROUND: Cell-free DNA (CFDNA) in the plasma/serum of patients with cancer
demonstrates tumour-associated genetic alterations, offering possibilities for diagnosis …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

The increasing knowledge of the molecular pathogenesis of cancer and the rapid
development of new molecular techniques are promoting the study of early molecular …

Fragments of cell-free DNA (cfDNA) in human body fluids often carry disease-specific
alterations and are now widely recognized as ideal biomarkers for the detection and …

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Background: Cell-free DNA is detectable in circulating blood. Numerous reports in the
literature have pointed out that cell-free DNA in plasma or serum has the clinical potential to …

In the course of the search for new biomarkers, circulating cell-free DNA (ccf-DNA) has
become a popular target of interest. An elevated level of ccf-DNA has been detected in the …

The discovery of cell-free tumor and fetal DNA molecules in the plasma of cancer patients
and pregnant women, respectively, has opened up exciting opportunities in molecular …